🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Delighted to receive the 2024 People's Choice Award at the EAS7 Networks Symposium on our MRFF funded research to improve medication information for people with dementia & carers. Many thanks to the CI team, our partners and consumers Sydney Health EMCR Sydney Health

Great Woolcock Institute of Medical Research seminar today by Dr Richard Russell on #Cardiovascular Risk in #COPD. #multimorbidity Richard Russell AstraZeneca

Mepolizumab reduces exacerbations in people with T2 inflammation and on triple. 👀 ⬇️.

On #WorldAsthmaDay, FIRS -Forum of International Respiratory Societies launches its Increasing Access to Inhaled Medicines campaign. The call is clear: Make Inhaled Treatments Accessible for ALL. These medicines work—lack of access is the barrier. Learn more➡️ bit.ly/4lYDPbH #LeaveNoOneBehind

Come and visit me at the Inogen Booth 326 and have a go at our #COPD cycling challenge 🚴🚴‍♀️🚴‍♂️

Phenotyping PH in COPD is a major challenge in respiratory medicine. Grateful for the great collaboration with the Strasbourg team. Our study is now out in ERJ Open Research Pulmotension InsermU999 Société de Pneumologie de Langue Française (SPLF) HTaPFrance publications.ersnet.org/content/erjor/…

The baseline findings poster of the #APCOMTrial, presented at the 2025 TSANZ Scientific Meeting, can be downloaded here: drive.google.com/file/d/1ml_qlK… #COPD #multimorbidity #primaryhealthcare

Honoured to have contributed to the global-first position statement on reducing cardiopulmonary risk in people with #COPD. Thank you for the opportunity, Prof Chris P Gale and John Hurst. #CVD #multimorbidity academic.oup.com/eurjpc/advance…

World first! MHRAgovuk approves the first pMDI for #COPD with a new propellant having near-zero global warning potential. pMDIs are essential medicines. Kudos to all involved. A good day for people living with COPD, and the 🌎. gov.uk/government/new…

#COPD

Glad to have presented last week's Woolcock Institute of Medical Research Friday seminar about my innovative research program on managing #COPD in the context of #multimorbidity. The seminar recording is available here: macquarie.zoom.us/rec/play/bIYAC… #publichealth #primaryhealthcare

Come and take me on in our #ATS2025 #COPD bike challenge. Can you beat the #copdathlete Find me at the Inogen booth #326

A landmark moment for global lung health! #WHA78 ERS and @europeanlung applaud adoption of historic lung health resolution on “Promoting and prioritizing an integrated lung health approach” at the 78th World Health Assembly. Read more: bit.ly/4dvVHa9

The International Cardiovascular & Respiratory Alliance, ICRA, is a global group that I founded & co-chair with Prof M Bhutani. We represent healthcare professionals, academics & patients from >40 countries. To join (free) email: [email protected]

#COPD & the Management of Cardiopulmonary Risk dovepress.com/chronic-obstru…

In theory, #DPP-1 inhibitors should work any neutrophilic #airway conditions such as #COPD. The key is finding the #neutrophilic #COPD patients.

🆕 The skin condition #panniculitis is a rare manifestation of #alpha1. The lack of evidence makes it difficult to treat, and those affected often experience diagnostic delay and significant symptoms. You can read more in this paper by Reem | ريم from my lab. Alpha-1 Foundation

Feeling of satisfaction completing the Gold Coast Marathon today with one of our children. I’ve now had the joy of doing an event with all four of them as well as one grandchild. Marathons are no longer about medals or times. It’s about the joy of the experience! #copd

The July issue of Respirology is now available online: onlinelibrary.wiley.com/toc/14401843/2…

Wonderful collaboration with Sadan Taher, Prof Alta Schutte, John Hurst and Prof Chris P Gale on this global-first systematic review: journals.sagepub.com/doi/10.1177/26… #COPD #HTN #CVD #multimorbidity #publichealth